Background:
Advances in the development of Direct-Acting Antivirals (DAAs), particularly
pangenotypic drugs, have led to a high rate of hepatitis C virus (HCV) eradication. Notably, real-
world studies have confirmed the efficacy and safety of pangenotypic DAA combinations reported
in registration trials. The aim of this study was to review the treatment recommendations, and the efficacy
and safety data of anti-HCV pangenotypic drugs reported in registration clinical trials and in
recent real-life cohort studies.
Methods:
We reviewed the efficacy and safety data of pangenotypic anti-HCV drug combinations
reported in original articles and in online conference abstracts.
Results:
Current pangenotypic drug combinations resulted in very high rates of sustained virologic
response and few adverse reactions in real-life settings. SVR12 rates in real-life studies ranged from
90-100% depending on the pangenotypic combination, the HCV genotype and the stage of liver disease.
Most adverse reactions reported in real-life settings were mild in intensity and rarely led to
treatment discontinuation. These results are in accordance with those of clinical trials.
Conclusion:
Pangenotypic DAAs result in very high rates of sustained virologic responses and are
well tolerated. However, they are contraindicated in patients with decompensated cirrhosis or advanced
chronic kidney disease who failed previous DDA-based treatment. Further research is required
to customize treatment to “unpackage” current DAA combinations and to develop generic
drugs against HCV.
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY